Welcome to MorphoSys

Founded some 20 years ago, MorphoSys is today one of the world's leading biotechnology companies. From a pure antibody platform enterprise, MorphoSys has matured into a renowned biopharmaceutical company with a rich pipeline of future therapeutic antibody products and a sustainable dual therapeutic business model. The Company’s aim is to continue pushing the boundaries of antibody generation in the industry – to engineer the medicines of tomorrow.


Innovation Capital

A new initiative through which MorphoSys provides innovation capital to promising start-ups.


YE Results 2014

Publication of MorphoSys's 2014 Consolidated Financial Statements.



  • 26/02/2015 // MorphoSys AG Reports Results for Fiscal Year 2014

    more …

  • 22/12/2014 // MorphoSys Announces Clinical Milestone in Oncology Program

    more …

Find more releases in the news overview


MorphoSys is interested in antibodies and biologics at late preclinical or early clinical stages.


YE Results 2014

02/26/2015- 02:00 p.m. CET - Conference Call and Webcast: Year End 2014 and Q4 Results